DNMT1 and myelodysplastic syndrome: FDA-approved DNMT1 inhibitors, including decitabine and azacitidine, are currently used to treat myelodysplastic syndromes; however, these drugs target the enzymatic activity of DNMT1 rather than its interaction with NAA10 [141,142].